The Prognostic Value of Olfactory Dysfunction in Patients with COVID-19: The COVIDORA Study.
Fiche publication
Date publication
février 2024
Journal
Life (Basel, Switzerland)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr JANKOWSKI Roger, Pr DEBRY Christian
Tous les auteurs :
Hamel AL, Delbos L, Natella PA, Radulesco T, Alexandru M, Bartaire E, Bartier S, Benoite G, Bequignon E, Castillo L, Canouï-Poitrine F, Carsuzaa F, Corré A, Coste A, Couloigner V, Daveau C, De Boissieu P, De Bonnecaze G, De Gabory L, Debry C, Deraedt S, Dufour X, El Bakkouri W, Gilain L, Hans S, Hautefort C, Hermann R, Jankowski R, La Croix C, Lecanu JB, Malard O, Michel J, Nguyen Y, Nevoux J, Papon JF, Patron V, Prigent M, Pruliere-Escabasse V, Renaud M, Rumeau C, Salmon D, Saroul N, Serrano E, Nhung Tran Khai C, Tringali S, Truy E, Vandersteen C, Verillaud B, Veil R, Fieux M
Lien Pubmed
Résumé
Among all studies describing COVID-19 clinical features during the first wave of the pandemic, only a few retrospective studies have assessed the correlation between olfac-tory dysfunction (OD) and the evolution of disease severity. The main aim was to assess whether OD is a predictive factor of COVID-19 severity based on the patient's medical management (outpa-tient care, standard hospital admission, and ICU admission).
Mots clés
COVID-19, anosmia, diabetes, hypertension, olfactory dysfunction, parosmia, phantosmia, renal insufficiency, risk factors, taste dysfunction, tobacco
Référence
Life (Basel). 2024 02 22;14(3):